Related Experiment Video
Updated: Mar 30, 2026

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
Published on: May 2, 2019
Clinical experiences with systemically administered siRNA-based therapeutics in cancer
Jonathan E Zuckerman1, Mark E Davis2
1Department of Pathology and Laboratory Medicine, University of California Los Angeles, Los Angeles, California 90095, USA.
Abstract:
Small interfering RNA (siRNA)-based therapies are emerging as a promising new anticancer approach, and a small number of Phase I clinical trials involving patients with solid tumours have now been completed. Encouraging results from these pioneering clinical studies show that these new therapeutics can successfully and safely inhibit targeted gene products in patients with cancer, and have taught us important lessons regarding appropriate dosages and schedules. In this Review, we critically assess these Phase I studies and discuss their implications for future clinical trial design. Key challenges and future directions in the development of siRNA-containing anticancer therapeutics are also considered.
Related Concept Videos
siRNA - Small Interfering RNAs
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Targeted Cancer Therapies
Experimental RNAi
Treatment Resistent Cancers
Treatment Resistant Cancers

